The potential of antisense oligonucleotide therapies for inherited childhood lung diseases
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2194-7791
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The potential of antisense oligonucleotide therapies for inherited childhood lung diseases ; volume:5 ; number:1 ; day:6 ; month:2 ; year:2018 ; pages:1-10 ; date:12.2018
Molecular and Cellular Pediatrics ; 5, Heft 1 (6.2.2018), 1-10, 12.2018
- Schlagwort
-
Endokrinologie
- Urheber
-
Martinovich, Kelly M.
- Beteiligte Personen und Organisationen
-
Shaw, Nicole C.
Kicic, Anthony
Schultz, André
Fletcher, Sue
Wilton, Steve D.
Stick, Stephen M.
SpringerLink (Online service)
- DOI
-
10.1186/s40348-018-0081-6
- URN
-
urn:nbn:de:1111-201804146757
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Martinovich, Kelly M.
- Shaw, Nicole C.
- Kicic, Anthony
- Schultz, André
- Fletcher, Sue
- Wilton, Steve D.
- Stick, Stephen M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Development of antisense oligonucleotide combinatorial therapies for spinal muscular atrophy (SMA)
Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders
Antisense oligonucleotide therapeutic approach for Timothy syndrome
Nonviral delivery systems for antisense oligonucleotide therapeutics
Macrophage inclusions in cerebrospinal fluid following treatment initiation with antisense oligonucleotide therapies in motor neuron diseases
Pharmacological studies of antisense oligonucleotide microRNA inhibitors
Profiled support vector machines for antisense oligonucleotide efficacy prediction
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases
CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction
Accessing Therapeutically‐Relevant Multifunctional Antisense Oligonucleotide Conjugates Using Native Chemical Ligation
Accessing Therapeutically‐Relevant Multifunctional Antisense Oligonucleotide Conjugates Using Native Chemical Ligation
Development of antisense oligonucleotide combinatorial therapies for spinal muscular atrophy (SMA)
Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders
Antisense oligonucleotide therapeutic approach for Timothy syndrome
Nonviral delivery systems for antisense oligonucleotide therapeutics
Macrophage inclusions in cerebrospinal fluid following treatment initiation with antisense oligonucleotide therapies in motor neuron diseases
Pharmacological studies of antisense oligonucleotide microRNA inhibitors
Profiled support vector machines for antisense oligonucleotide efficacy prediction
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases
CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction
Accessing Therapeutically‐Relevant Multifunctional Antisense Oligonucleotide Conjugates Using Native Chemical Ligation
Accessing Therapeutically‐Relevant Multifunctional Antisense Oligonucleotide Conjugates Using Native Chemical Ligation
Development of antisense oligonucleotide combinatorial therapies for spinal muscular atrophy (SMA)
Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders
Antisense oligonucleotide therapeutic approach for Timothy syndrome
Nonviral delivery systems for antisense oligonucleotide therapeutics
Macrophage inclusions in cerebrospinal fluid following treatment initiation with antisense oligonucleotide therapies in motor neuron diseases
Pharmacological studies of antisense oligonucleotide microRNA inhibitors
Profiled support vector machines for antisense oligonucleotide efficacy prediction
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases
CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction
Accessing Therapeutically‐Relevant Multifunctional Antisense Oligonucleotide Conjugates Using Native Chemical Ligation